AIGH Capital Management LLC Grows Holdings in Coya Therapeutics, Inc. (NASDAQ:COYA)

AIGH Capital Management LLC lifted its position in Coya Therapeutics, Inc. (NASDAQ:COYA) by 85.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,201,152 shares of the company’s stock after buying an additional 551,725 shares during the quarter. Coya Therapeutics makes up 2.2% of AIGH Capital Management LLC’s investment portfolio, making the stock its 17th largest holding. AIGH Capital Management LLC owned approximately 7.19% of Coya Therapeutics worth $6,883,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Newbridge Financial Services Group Inc. purchased a new position in shares of Coya Therapeutics during the fourth quarter worth about $401,000. CM Management LLC boosted its holdings in shares of Coya Therapeutics by 11.1% in the fourth quarter. CM Management LLC now owns 160,000 shares of the company’s stock valued at $917,000 after acquiring an additional 15,941 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock worth $918,000 after acquiring an additional 4,485 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Price Performance

COYA opened at $6.56 on Friday. Coya Therapeutics, Inc. has a 12 month low of $4.75 and a 12 month high of $10.24. The stock has a market capitalization of $109.72 million, a P/E ratio of -10.09 and a beta of 0.31. The business has a 50 day simple moving average of $6.43 and a 200-day simple moving average of $6.52.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.14. The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.10 million. Research analysts anticipate that Coya Therapeutics, Inc. will post -1.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. D. Boral Capital restated a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Thursday. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, March 20th.

Coya Therapeutics Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.